This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Polygala tenuifolia
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict WATCH-LIST LOW
Promising preclinical signal (BDNF/NGF upregulation, AChE inhibition similar to but milder than huperzine A) but human RCT evidence is sparse and largely from Korean BT-11 trials in dementia cohorts. Subjective reports are mixed: some users report dream vividness + memory-recall boost, others report nausea + anxiety. Glycine-NMDA partial modulation is the most interesting mechanism for cognitive plasticity but is not well-mapped pharmacokinetically in humans. Verdict flips to OPTIONAL-ADD if Korean BT-11 dementia RCTs replicate at standard supplement dose, or if a clean self-experiment shows reliable recall improvement without GI side effects. Stays at WATCH-LIST otherwise because [[lions-mane]] + [[bacopa-monnieri]] cover similar ground with better human data.
▸ Sourcing deep dive
Widely available as raw root, 10:1 extract, and standardized BT-11-style extracts. Quality varies. Nootropics Depot and Double Wood carry standardized forms.
▸ Verdict change log
- 2026-06-05 — Initial verdict WATCH-LIST. Preclinical interesting, human data thin, redundant with bacopa + lion's mane. (stub)
▸ Open questions / gaps Open
- Whether the BDNF/NGF signal translates to functional outcomes in healthy users (not just dementia cohorts).
- Whether the dream-vividness effect is glycine-NMDA-mediated and predicts memory benefit.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.